Details of the Drug Combination

General Information of Drug Combination (ID: DCBID3N)

Drug Combination Name
Zonisamide Zonisamide
Indication
Disease Entry Status REF
Weight Gain Phase 3 [1]
Component Drugs Zonisamide   DM0DTF7 Zonisamide   DM0DTF7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Zonisamide
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [2]
Alcohol use disorder 6C40.2 Approved [2]
Bipolar disorder 6A60 Approved [2]
Epilepsy 8A60-8A68 Approved [3]
Zonisamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [4]
------------------------------------------------------------------------------------
Zonisamide Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [9]
Aldehyde oxidase (AOX) DE8UGTM A0A1V9IQJ2_CLOSG Metabolism [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Zonisamide Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tyrosine 3-monooxygenase (TH) OT6ZORKP TY3H_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------
Indication(s) of Zonisamide
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [2]
Alcohol use disorder 6C40.2 Approved [2]
Bipolar disorder 6A60 Approved [2]
Epilepsy 8A60-8A68 Approved [3]
Zonisamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [4]
------------------------------------------------------------------------------------
Zonisamide Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [9]
Aldehyde oxidase (AOX) DE8UGTM A0A1V9IQJ2_CLOSG Metabolism [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Zonisamide Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tyrosine 3-monooxygenase (TH) OT6ZORKP TY3H_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00363376) A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
2 Zonisamide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7047).
4 Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
5 Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
6 Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
7 Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
8 Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
9 Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
10 The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997 Mar;49(3):253-6.
11 [The discovery of an antiparkinsonian drug, zonisamide]. Rinsho Shinkeigaku. 2010 Feb;50(2):67-73. doi: 10.5692/clinicalneurol.50.67.